Investigating inflammation in obesity-related diseases
Inflammation and Obesity-associated Disease
This study is testing how inflammation in fat tissue affects the health of people with obesity-related diseases like heart problems and liver issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Göteborg University Academic / other |
| Locations | 1 site (Gothenburg) |
| Trial ID | NCT02322073 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between visceral obesity, adipose inflammation, and the development of obesity-related diseases such as cardiometabolic disease, liver cirrhosis, and chronic kidney disease. The researchers hypothesize that impaired production of specialized pro-resolving mediators (SPMs) leads to increased inflammation and fibrosis in adipose tissue, contributing to systemic health issues. The study will compare the pro-resolving lipid profiles of obese individuals with and without metabolic diseases and examine the effects of anti-inflammatory agents on human adipose macrophages in ex vivo cultures.
Who should consider this trial
Good fit: Ideal candidates for this study are obese individuals with a BMI between 35-55 kg/m2 and lean individuals with a BMI between 18.5-24.9.
Not a fit: Patients undergoing medical treatment with NSAIDs, corticosteroids, or immune-suppressants, as well as those with smoking or alcohol abuse issues, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies for managing obesity-related diseases by targeting inflammation.
How similar studies have performed: While the specific approach of investigating pro-resolving mediators in obesity-related diseases is relatively novel, similar studies have shown promising results in understanding the role of inflammation in metabolic disorders.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Obese BMI 35-55 kg/m2 * Lean BMI 18.5-24.9 Exclusion Criteria: * Medical treatment with NSAIDs, corticosteroid treatment, immune-suppressants. * Other: smoking, alcohol abuse.
Where this trial is running
Gothenburg
- Sahglrenska University Hospital — Gothenburg, Sweden (Recruiting)
Study contacts
- Study coordinator: Ville R Wallenius, MD, PhD.
- Email: ville.wallenius@gastro.gu.se
- Phone: +46313421000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.